Thanks for that post. Seems that there's a consensus regarding BG-12 becoming the biggest drug in MS in time. Aubagio doesn't look like a great choice considering its limited efficacy and tox and certainly not a 1st line drug. Alemtuzumab's safety issues will very much limit its use. No mention of Gilenya just next gen S1P1 compounds?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.